The market for injectable anti-HIV therapeutics will be worth $28 billion by 2029, according to projections from the analyst and consulting firm GlobalData.
GlobalData valued the broader HIV therapeutics market at $22.9 billion in 2019 across the U.S., France, Germany, Italy, Spain, U.K. and Japan.
While the overall market is growing at a low single-digit rate, injectable therapies will likely see more brisk growth, GlobalData projects.
To date, the majority of HIV therapies are orally-delivered antiretroviral drugs although a handful of injectable drugs have hit been introduced over the years.
Future injectable anti-HIV therapies could be administered less frequently than oral drugs.
One early injectable anti-HIV therapy, Fuzeon (enfuvirtide) from Roche (OTCMKTS:RHHBY), is administered multiple times per day, posing a challenge for adh…